Teichos Laboratories, LLC

Teichos Laboratories, LLC, doing business as Teichos Laboratories LLC, is a limited liability company structured as a partnership or limited liability partnership. It is registered in SAM.gov to receive federal awards from the U.S. government.

Teichos Laboratories has been awarded several prime federal contracts from agencies like the National Institutes of Health's National Institute of Allergy and Infectious Diseases. These contracts have focused on research and development efforts, such as augmenting the quality and duration of immune responses using novel adjuvant combinations like a TLR2 agonist-aluminum adjuvant. The firm has received firm fixed price definitive contracts set aside for total small business participation, with funding amounts around $300,000 per award. Some of these were Phase I SBIR awards under solicitations seeking innovative solutions in areas like infectious diseases from small businesses.

Through federal grant awards, Teichos Laboratories has also received project grant funding from agencies like the National Heart, Lung, and Blood Institute and Centers for Disease Control and Prevention. A notable $778,839 grant from NHLBI supported the development of a new tolerizing vaccine adjuvant called TL-003 to treat Factor VIII resistance in Hemophilia A patients. This project aimed to establish preclinical data on TL-003's mechanisms and effects on inhibitor production using Teichos' synthetic peptidoglycan molecules. Another $243,000 CDC grant funded work on a synthetic immunostimulator targeting toll-like receptor 2 and NOD2 to improve influenza vaccines. Teichos has carried out this grant-funded research at facilities in West Lafayette and Indianapolis, Indiana.

Teichos Laboratories, LLC. is a research-focused immunotherapyy company based in Indianapolis, Indiana. We make totally synthetic versions of nature's warning signals to direct immune responses in humans and animals.